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Summary
Calorie restriction (CR) without malnutrition slows aging in animal models. Oxidative
stress reduction was proposed to mediate CR effects. CR effect on urinary F2-iso-
prostanes, validated oxidative stress markers, was assessed in CALERIE, a two-year
randomized controlled trial. Healthy volunteers (n = 218) were randomized to
prescribed 25% CR (n = 143) or ad libitum control (AL, n = 75) stratifying the ran-
domization schedule by site, sex, and BMI. F2-isoprostanes were quantified using
LC-MS/MS in morning, fasted urine specimens at baseline, at 12 and 24 months.
The primary measure of oxidative status was creatinine-adjusted 2,3-dinor-iPF(2a)-
III concentration, additional measured included iPF(2a)-III, iPF2a-VI, and 8,12-iso-
iPF2a-VI. Intention-to-treat analyses assessed change in 2,3-dinor-iPF(2a)-III using
mixed models assessing treatment, time, and treatment-by-time interaction effects,
adjusted for blocking variables and baseline F2-isoprostane value. Exploratory analy-
ses examined changes in iPF(2a)-III, iPF(2a)-VI, and 8,12-iso-iPF(2a)-VI. A factor
analysis used aggregate information on F2-isoprostane values. In CR group,
2,3-dinor-iPF(2a)-III concentrations were reduced from baseline by 17% and 13% at
12 and 24 months, respectively; these changes were significantly different from AL
group (p < .01). CR reduced iPF(2a)-III concentrations by 20% and 27% at 12 and
24 months, respectively (p < .05). The effects were weaker on the VI-species. CR
caused statistically significant reduction in isoprostane factor at both time points,
and mean (se) changes were 0.36 (0.06) and 0.31 (0.06). No significant changes
in isoprostane factor were at either time point in AL group (p < .01 between-group
difference). We conclude that two-year CR intervention in healthy, nonobese men
and women reduced whole body oxidative stress as assessed by urinary concentra-
tions of F2-isoprostanes.
K E YWORD S
caloric restriction, oxidative stress, randomized controlled trial
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2018 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
Accepted: 1 December 2017
DOI: 10.1111/acel.12719
Aging Cell. 2018;17:e12719.
https://doi.org/10.1111/acel.12719
wileyonlinelibrary.com/journal/acel | 1 of 9
Funding information
This project was supported by grants
U01AG022132, U01AG020478,
U01AG020487, U01AG020480, and U24-
AG047121 from the National Institute on
Aging; grants P30DK056341 and
P30DK072476 from the National Institute
of Diabetes and Digestive and Kidney
Disease.
1 | INTRODUCTION
Caloric restriction (CR) without malnutrition is the most powerful
known intervention to slow aging and protect against cancer, heart
disease, type 2 diabetes, and cognitive decline in many eukaryotic
organisms, particularly rodents and monkeys (de Cabo, Carmona-
Gutierrez, Bernier, Hall & Madeo, 2014; Fontana, Partridge & Longo,
2010; Mattison et al., 2017). Multiple mechanisms have been
hypothesized to mediate these beneficial effects of CR on aging,
including a reduction in oxidative stress (de Cabo et al., 2014; Fon-
tana et al., 2010). In rodents, CR decreases markers of oxidative
stress and damage in multiple tissues (Sohal & Weindruch, 1996;
Walsh, Shi & Van Remmen, 2014). However, there are currently no
data from randomized controlled trials in humans evaluating the
long-term effects of CR on reliable markers of oxidative stress.
Oxidative stress and the accumulation of oxidative injury are
deeply implicated in the pathogenesis of multiple age-associated
chronic diseases, including heart disease, type 2 diabetes, cancer,
and neurodegeneration (Valko, Jomova, Rhodes, Kuca & Musilek,
2016). Urinary F2-isoprostanes generated from polyunsaturated fatty
acids constitute the validated index of oxidative damage in animal
models, and the most reliable markers of nonenzymatic lipid peroxi-
dation in vivo in humans (Basu, 2008; Il’yasova, Scarbrough & Spaso-
jevic, 2012; Il’yasova et al., 2010; Kadiiska et al., 2005; Milne,
Musiek & Morrow, 2005). High urinary F2-isoprostane concentra-
tions are found in patients with type 2 diabetes, hypercholes-
terolemia, coronary artery disease, and obesity (Basu, 2008; Valko
et al., 2016). The purpose of CALERIE study—a 2-year multicenter
randomized controlled trial (RCT)—was to evaluate the effects of a
prescribed 25% CR diet in healthy, nonobese young, and middle-
aged individuals on proposed longevity biomarkers and CR-induced
metabolic adaptations. One of the targeted biomarkers was urinary
F2-isoprostanes, well-characterized and stable markers of oxidative
stress (Zhang et al., 2010). In an animal study (Ward et al., 2005)
and in a short-term intervention (Buchowski et al., 2012), F2-iso-
prostanes were reduced in response to CR. We measured urinary
concentration of 2,3-dinor-iPF(2a)-III, as the primary indicator of
oxidative status, and in addition to three F2-isoprostane isomers: iPF
(2a)-III, iPF2a-VI, and 8,12-iso-iPF2a-VI. Our primary hypothesis for
this analysis—caloric restriction reduces systemic levels of oxidative
damage, specifically lipid peroxidation—was based on the effects of
long-term caloric restriction in laboratory animals and/or shorter-
term human trials (Heilbronn et al., 2006; Sohal & Weindruch, 1996;
Walsh et al., 2014). 2,3-dinor-iPF(2a)-III was selected as the primary
measure of oxidative stress, because this is a beta-oxidation metabo-
lite of the most frequently measured isomer iPF(2a)-III (Basu, 2008;
Milne et al., 2005). Selection of 2,3-dinor-iPF(2a)-III was also based
on a theoretical concern that renal tissues may contribute dispropor-
tionally to the total production of iPF(2a)-III, whereas beta-oxidation
occurs predominantly in the extra-renal tissues; the measurements
of the beta-oxidation metabolites may have circumvented this prob-
lem. Also, urinary concentrations of 2,3-dinor-iPF(2a)-III are several
fold greater as compared to its precursor iPF(2a)-III, thus reducing
measurement error. Measurements of multiple F2-isoprostane spe-
cies provided the opportunity to assess the effect of CR intervention
on an aggregate F2-isoprostane measure through factor analysis.
2 | RESULTS
The study design has been previously reported (Rochon et al., 2011)
and the main findings have been published (Ravussin et al., 2015).
As previously reported, the study population was predominantly
white, and approximately 70% women (Table 1). According to the
enrollment criteria, mean BMI was slightly above the threshold for
overweight; mean age was approximately 38 years (Table 1). At
baseline, there was no difference in urinary creatinine or urinary
F2-isoprostane concentrations between the CR and AL groups.
We examined crude cross-sectional associations between urinary
F2-isoprostanes and participant characteristics known to be associ-
ated with these biomarkers in other study populations (Table 2)
(Il’yasova, Wang, et al., 2012; Kanaya et al., 2011; Keaney et al.,
2003). As expected, urinary F2-isoprostane concentrations were
greater in women, with the least female–male difference being in
8,12-iso-iPF(2a)-VI (not statistically significant). Overall, F2-isopros-
tane concentrations tended to be lower in African American partici-
pants compared to Caucasians (Table 3). There was no correlation of
urinary F2-isoprostanes with age or BMI (Table 2).
The ITT analysis of the intervention effect showed that the
reduction in 2,3-dinor-iPF(2a)-III concentrations was significantly
greater in the CR as compared to the AL group at both time points,
12 and 24 months (Table 3, Figure 2). Specifically, 2,3-dinor-iPF(2a)-
III levels decreased at 12 months with eightfold greater change in
the CR group (p = .0001). At 24 months, 2,3-dinor-iPF(2a)-III
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concentrations reverted to baseline in both groups: In the AL group,
the concentrations were not different from baseline; in contrast, 2,3-
dinor-iPF(2a)-III concentrations in the CR group remained
significantly reduced from baseline (p = .006). CR also significantly
reduced urinary concentrations of iPF(2a)-III at 12 and 24 months
(p-values .04 and .003, respectively); because this is the most fre-
quently studied F2-isoprostane species, the observed effect on iPF
(2a)-III concentrations provides a reference to previously published
F2-isoprostane studies.
F2-isoprostanes are formed by nonenzymatic oxidation of arachi-
donic acid, and this process produces a mix of isomers with different
positions of the oxygenated carbons—the III, IV, V, and VI series
(Rokach et al., 1997). Therefore, in addition to the two F2-isopros-
tanes from the III series, we measured two species from the VI ser-
ies (which are less well studied, but abundant and potentially more
sensitive markers of oxidative status (Pratico, Lawson, Rokach &
FitzGerald, 2001; Dentchev, Yao, Pratico & Dunaief, 2007)). The
adjusted effects of caloric restriction on VI series species were
weaker than on III series (Table 3, Figure 1). There was no treat-
ment-by-time interaction in any examined measure of F2-isopros-
tanes. The general pattern of changes in urinary F2-isoprostane
concentrations was similar to weight changes in the AL- and CR
groups (Figure 1).
A strong correlation between the four measured F2-isoprostane
species was observed. To take advantage of this intercorrelation, we
performed a factor analysis using all four F2-isoprostane species.
First, the four F2-isoprostane variables at baseline were normalized
(mean = 0, SD = 1). The eigenvalue for the best linear combination
of the four F2-isoprostanes was 3.22, indicating that the factor
explained 80.4% of the variance in the variables; correlations were
0.80, 0.77, 0.92, 0.72 between the factor and the four F2-isopros-
tanes. That is, the summary scale contained 80.4% of the informa-
tion contained in the four F2-isoprostane markers. As no additional
factor had an eigenvalue greater than 1, we chose to model a single
factor, called isoprostane factor. By definition, isoprostane factor
TABLE 1 Demographic, anthropometric, and clinical
characteristics at baseline for the 218 participants who started the
2-year intervention
Ad libitum
(n = 75)
Caloric restriction
(n = 143)
N (%)
Sex
Female 53 (70.7) 99 (69.2)
Male 22 (29.3) 44 (30.8)
Race
White 57 (76) 111 (77.6)
African
American
11 (14.7) 15 (10.5)
Other 7 (9.3) 17 (11.9)
Mean (SD)
Age, year 37.9 (6.94) 38.0 (7.34)
BMI, kg/m2 25.1 (1.64) 25.2 (1.78)
Creatinine, mg/ml 0.613 (0.224) 0.720 (0.350)
Urinary F2-isoprostanes, ng/mg creatinine
Primary measure
2,3-dinor-iPF(2a)-III 1.90 (0.86) 1.89 (0.81)
Secondary measures
iPF(2a)-III 0.211 (0.138) 0. 209 (0.124)
iPF(2a)-VI 4.05 (1.55) 4.12 (1.80)
8,12-iso-iPF(2a)-VI 5.35 (2.35) 5.43 (2.41)
AL, ad libitum control group; CR, 25% caloric restriction group.
TABLE 2 Baseline Urinary F2-isoprostane Levels and Characteristics of CALERIE participants (n = 218)
2,3-dinor-iPF2(2a)-III iPF(2a)-III iPF(2a)-VI 8,12-iso-iPF(2a)-VI
Mean (SD) p-value for Wilcoxon test
Sex
Females 2.10 (0.86) 0.238 (0.139) 4.47 (1.84) 5.55 (2.57)
Males 1.41 (0.47) 0.145 (0.630) 3.25 (0.97) 5.06 (1.85)
p < .0001 p < .0001 p < .0001 p = .55
Race/ethnicity
Caucasian 1.89 (0.84) 0.215 (0.133) 4.15 (1.82) 5.58 (2.51)
African American 1.94 (0.94) 0.187 (0.132) 3.82 (1.41) 4.26 (1.29)
Other 1.86 (0.55) 0.196 (0.990) 4.04 (1.22) 5.34 (2.06)
p = .86 p = .28 p = .58 p = .02
Spearman correlation coefficient
p-value
Age 0.1125
p = .10
0.0429
p = .53
0.0360
p = .60
0.0691
p = .31
BMI 0.0365
p = .59
0.0008
p = .99
0.0125
p = .86
0.0757
p = .27
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scores had a mean = 0.0 and SD = 1 at baseline. Next, the iso-
prostane factor was defined for the two follow-up points
(12 months and 24 months), using the scoring and the normalization
coefficients defined at baseline. Thus, any differences from 0 in the
follow-up levels of the factor should be interpreted as the propor-
tion of a standard deviation value difference from the baseline mean.
Testing of the intervention effect (CR vs AL) on changes in the iso-
prostane factor was conducted similar to the primary hypothesis
(Table 3). For the AL group, there was approximately a 1/10th SD
decrease in the isoprostane factor (0.098 SD), whereas the
decrease in the CR group was (0.358 SD) approximately 3.6-fold
greater (p = .004). This relative difference between the treatment
groups increased to a 6.4 greater change at 24 months (0.048 vs.
0.311 SD, p = .006) (Table 3). However, we did not observe a
treatment-by-time difference in the effect (p = .97, for the time-by-
treatment interaction).
2.1 | Variables associated with F2-isoprostane
changes in the CR and AL groups
At baseline, urinary 2,3-dinor-iPF(2a)-III concentration was positively
associated with fasting leptin (rs = 0.476, p < .0001), HMW adipo-
nectin (rs = 0.342, p < .0001), C-reactive protein (rs = 0.274,
p < .0001), fasting insulin (rs = 0.159, p = .019), and triiodothyronine
(rs = 0.161, p = .018), and inversely with insulin sensitivity
(rs = 0.159, p = .019). However, in response to the intervention,
only changes in leptin and insulin sensitivity were significantly corre-
lated with changes in urinary 2,3-dinor-iPF(2a)-III concentration (Fig-
ure 2). In particular, changes in leptin concentration were directly
correlated with changes in urinary 2,3-dinor-iPF(2a)-III concentration
(rs = 0.326, p < .0001 for both groups combined; rs = 0.263,
p = .0037 for CR group only). In contrast, change in urinary 2,3-
dinor-iPF(2a)-III concentration was inversely correlated with change
in the insulin sensitivity (rs = 0.234, p = .0012 for both groups
combined; rs = 0.193, p = .035 for CR group only).
3 | DISCUSSION
Two years of CR in healthy, young and middle-age nonobese individ-
uals resulted in a significant and persistent reduction in urinary 2,3-
dinor-iPF(2a)-III and iPF(2a)-III concentrations, reflecting lower accu-
mulation of oxidative damage in multiple human tissues during the
two-year period. Urinary 2,3-dinor-iPF(2a)-III concentrations were
17% and 13% lower after 1 and 2 years of CR, respectively. This
reduction in urinary F2-isoprostane concentrations in our CR volun-
teers was associated with a CR-induced reduction in leptin and
improved insulin sensitivity.
Whether or not oxidative stress plays a role in the biology of
aging is still unclear (Perez et al., 2009); but, multiple lines of
research indicate that oxidative stress is deeply implicated in the
pathogenesis of several age-related chronic diseases, including car-
diovascular disease and cancer and it is considered a prevailing the-
ory of human aging (Basu, 2008; Valko et al., 2016). In particular,
obesity is associated with increased oxidative stress, and weight loss
reduces urinary F2-isoprostane levels in obese women (Davi et al.,
2002; Duggan et al., 2016; Kanaya et al., 2011; Keaney et al., 2003).
To the best of our knowledge, it is not known whether CR reduces
TABLE 3 Adjusted Changes in Urinary F2-isoprostane Levelsa at 12 and 24 Months from Baseline by Treatment Group
ng/mg creatinine
AL
N = 75
CR
N = 143
p value
AL vs. CR P (time 3 treatment)
Primary analysis
2,3-dinor-iPF(2a)-III
Change at 12 months 0.041  0.059 0.313  0.045 .0001 0.833
Change at 24 months 0.018  0.075 0.237  0.058 .006
Exploratory analyses
iPF(2a)-III
Change at 12 months 0.012  0.012 0.042  0.009 .04 0.486
Change at 24 months 0.016  0.011 0.057  0.009 .003
iPF(2a)-VI
Change at 12 months 0.171  0.140 0.461  0.105 .08 0.846
Change at 24 months 0.115  0.157 0.213  0.121 .09
8,12-iso-iPF(2a)-VI
Change at 12 months 0.303  0.170 0.751  0.128 .058 0.428
Change at 24 months 0.381  0.184 0.663  0.141 .42
Isoprostane Factor
Change at 12 months 0.098 (0.075) 0.358 (0.057) .004 0.974
Change at 24 months 0.048 (0.078) 0.311 (0.060) .006
aAdjusted for site, sex, BMI, and baseline values of F2-isoprostanes
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F2-isoprostanes in men, and most importantly in nonobese individu-
als. In our study, we observed that CR significantly reduced multiple
F2-isoprostane species in nonobese healthy men and women, and
there was a significant correlation between change in serum leptin
and urinary 2,3-dinor-iPF(2a)-III concentrations.
It is well accepted that fat mass determines plasma leptin
concentrations and that excessive adiposity is associated with
elevated circulating leptin levels (Considine et al., 1996); this plays
a key role in obesity-induced oxidative stress (Milagro, Campion &
Martinez, 2006). Injection of leptin significantly increases urinary
F2-isoprostanes in mice, probably by increasing the production
of reactive intermediates such as H2O2 and hydroxyl radical
through NOX activation (Beltowski, Wojcicka & Jamroz,
2003; Fortuno et al., 2010). Moreover, leptin may reduce the
activity of the cellular antioxidant paraoxonase-1 (PON-1), which
in turn increases oxidative stress (Beltowski et al., 2003). Consis-
tent with these previously published findings, we observed a sig-
nificant correlation between the change in plasma leptin
concentration and the change in urinary 2,3-dinor-iPF(2a)-III con-
centration.
F IGURE 1 Change in urinary F2-
isoprostane concentrations and in body
weight within CR and AL groups. Percent
change in each F2-isoprostane species as
compared to the baseline level: (a) 2,3-
dinor-iPF(2 a)-III, (b) iPF(2a)-III, (c) iPF(2 a)-
VI, (d) 8,12-iso-iPF(2a)-VI, (e) body weight
F IGURE 2 Correlations between
changes in 2,3-dinor-iPF(2 a)-III and two
metabolic characteristics during the 2-year
intervention: (a) correlation with changes in
plasma leptin levels and (b) correlation with
changes in insulin sensitivity
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The decline of insulin resistance, a key risk factor for several
common cancers, may also mediate CR-related reduction in oxidative
stress (Longo & Fontana, 2010). Insulin resistance induced by exces-
sive adiposity may increase the risk of developing cancer because of
compensatory hyperinsulinemia and increased bioavailability of IGF1
(due to reduced IGFBP-1 production), thereby up-regulating the
PI3K/AKT pathway and stimulating cell proliferation and genomic
instability (Longo & Fontana, 2010). AKT activation inhibits the
nuclear translocation of FOXO, resulting in a downregulation of
DNA repair (i.e., DDB1) genes, and in an increase in cell proliferation
(Cyclin D) and multiple antioxidant genes, such as SOD2 and catalase
(Webb & Brunet, 2014). Accordingly, we found in this study a corre-
lation between fasting insulin and urinary 2,3-dinor-iPF(2a)-III con-
centration at baseline. Further, there was a significant inverse
correlation whereby reductions in urinary 2,3-dinor-iPF(2a)-III con-
centrations corresponded with improved insulin sensitivity.
The CR diet intervention did not mandate a particular dietary
composition. Rather participants could self-select their own diet,
with dietary intake likely to vary throughout the trial in order for
participants to remain adherent to the weight loss trajectory that
fostered the desired level of CR. As changes in diet composition
were not uniform across participants, it is unlikely that dietary
changes can explain the observed reduction in F2-isoprostanes.
The strengths of this work include the RCT design, highly struc-
tured and supervised 2-year CR intervention in young and middle-
aged healthy normal weight or slightly overweight men and women,
and comprehensive assessments of body composition and oxidative
stress throughout the intervention. These strengths point to the
observed responses being related to basic biological functions and
not to those necessarily related to disease. These observations are
also consistent with the marked improvements in cardiometabolic
risk factors, including systolic and diastolic blood pressures, triglyc-
erides, total cholesterol and glucose control (HOMA-IR) observed in
the CALERIE study (Ravussin et al., 2015). The consistency of the
trends across all four F2-isoprostane species led us to the conclusion
that the overall oxidative status measured by these biomarkers can
be summarized by an integrated function, the isoprostane factor.
The high correlations between the isoprostane factor and each of
the F2-isoprostane species (.72 ≤ r ≤ .90) suggest that the four
examined F2-isoprostane species reflect the biological processes are
closely related. However, caloric restriction induced greater changes
in the III series species, indicating that F2-isoprostane III series
appear to be more sensitive to CR intervention than the VI series. It
could be that metabolic pathways affected by CR favor formation of
the III series F2-isoprostane isomers.
In conclusion, data from this large randomized clinical trial
showed that even in young and middle-aged healthy lean or slightly
overweight men and women, sustained CR significantly reduces
oxidative stress, as reflected in lower urinary concentration of multi-
ple F2-isoprostane series. More studies are needed to understand
the biological implications of reducing the accumulation of molecular
damage leading to age-associated chronic diseases, and whether or
not other less drastic nutritional interventions in humans (e.g.,
intermittent fasting, moderate protein, or essential amino acid
restriction) may mimic these effects. Of note, individuals in this
study self-selected their CR diet. Thereby, future CR studies that
help participants to consume foods which provide antioxidant bene-
fits may realize a greater benefit on markers of oxidative stress. The
future implications of this work on long-term aging remain to be
studied.
4 | EXPERIMENTAL PROCEDURES
4.1 | Participants and study design
The rationale and study design of CALERIE Phase 2 have been previ-
ously described (Rochon et al., 2011). CALERIE 2 was a two-year
randomized controlled trial (RCT) that recruited healthy volunteers
to receive an intervention designed to either reduce energy intake
by 25% (CR group) or to maintain intake on an ad libitum basis (AL
group). Eligibility criteria included men 20–50 years of age (inclusive)
and women 21–47 years of age (inclusive) and required participants
to be normal weight or slightly overweight (22.0 ≤ BMI<28.0 kg/m2)
at the screening visit. A comprehensive screening procedure identi-
fied volunteers who were healthy to participate in a two-year RCT
of caloric restriction and adhere to the rigors of the study. Partici-
pants were randomized to 25% caloric restriction (CR) or ad libitum
control (AL) in a 2:1 ratio; randomization was stratified for site, sex
and BMI. Study interventions: From day 1, the CR intervention tar-
geted a sustained 25% restriction of energy intake prescribed on the
basis of the energy requirements determined from two, 2-week dou-
bly labeled water measures at baseline (Rickman et al. 2011; Redman
et al. 2014). Adherence to 25% CR was fostered by regular group
and individual meetings with trained interventionists, and a predicted
weight loss trajectory was used as a guide to keep participants on
track. Participants randomized to the control group were advised to
continue their current diets on a completely ad libitum basis. No
specific level of physical activity was required or recommended for
either group. All participants received a multivitamin (Nature Made
Multi Complete, Pharmavite LLC, Mission Hills, CA, USA) and cal-
cium supplement (1000 mg/d, Douglas laboratories, Pittsburgh, PA,
USA) to foster nutritional adequacy of the self-selected diets. The
study was approved by the institutional review boards at Pennington
Biomedical Research Center, Washington University, Tufts Univer-
sity, and Duke University. Study oversight was provided by a Data
and Safety Monitoring Board and registered at ClinicalTrials.gov
NCT00427193. Full details of the trial can be found at calerie.-
duke.edu.
4.2 | Clinical outcome assessments
Subjects were followed throughout the course of the two-year study
at clinical visits at each respective study site according to a manual
of procedures. Urine and blood samples were obtained during an
inpatient stay, in the morning following an overnight fast. Samples
were processed in real time and were stored frozen until assays
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were performed at the end of the study. Analytes were measured
at the University of Vermont Core Laboratory. Leptin (Linco
Panel B, catalog number HADK2-61K-B), high molecular weight
(HMW) adiponectin (R&D ELISA, Catalog number DRP300), and
high-sensitivity C-reactive protein (BNII Nephelometer, OQ1Y21,
OQ1Y13) were measured using ELISA. Fasting insulin (Elecsys,
Roche Diagnostics, Indianapolis, IN, USA) and triiodothyronine were
measured using a chemiluminescent immunoassay in an Immulite
analyzer. Matsuda insulin sensitivity index was a measure derived
from fasting insulin.
4.3 | Measurements of urinary F2-isoprostanes and
creatinine
Concentration of F2-isoprostanes in urine was adjusted for urinary
creatinine to account for different urine diluteness between individu-
als, which varies depending on how much liquids a person ingested
and how much was reabsorbed in the kidneys (Levey et al., 2005).
Four isomers of F2-isoprostanes—iPF(2a)-III, 2,3-dinor-iPF(2 a)-III,
iPF(2 a)-VI, and 8,12-iso-iPF(2a)-VI—and creatinine were quantified
by liquid chromatography-tandem mass spectrometry (LC-MS/MS)
on Shimadzu 20A series LC and Applied Biosystems API 4000 QTrap
MS/MS instruments as previously described (Il’yasova et al., 2010).
Based on creatinine measurements, the urine samples were diluted
to 0.65 mg/ml creatinine, and samples with creatinine levels equal to
or below this value were analyzed without dilution. Sample prepara-
tion included addition of internal standards [iPF(2a)-III-d4, 8,12-iso-
iPF(2a)-VI-d11, iPF(2a)-VI-d4] and 10 ll 1M HCl; washing of sam-
ples (500 ll) with 1 ml hexane; extraction of the analytes by ethyl
acetate/hexane mixture (3/1, v/v); evaporation of the liquid; and
resuspension of the residue in 150 ll of a mixture containing 70%
mobile phase A (0.1% formic acid in water) and 30% methanol. Using
LC-MS/MS, 100 ll of sample was injected into two solid-core C18
columns (Phenomenex Kinetex C18, 150 9 4.6 mm) in series to
achieve chromatographic separation of the F2-isoprostane isomers.
The mass spectrometer was operated in negative mode with the fol-
lowing MRM transitions (m/z): 353/193 [iPF(2a)-III], 357/197 [iPF
(2a)-III-d4], 325/237 [2,3-dinor-iPF(2a)-III], 353/115 [iPF(2a)-VI and
8,12-iso-iPF(2a)-VI], 364/115 [iPF(2a)-VI-d11], and 357/115 [8,12-
iso-iPF(2a)-VI-d4]. Calibration samples covering the expected range
of concentrations were prepared by adding pure material into pooled
human urine, injected before and after the patient samples. Lower
limits of quantification (LLOQ >80% accuracy) were 0.007, 0.34,
0.25, and 0.12 mg/ml for iPF(2a)-III, 2,3-dinor-iPF(2a)-III, iPF(2a)-VI,
and 8,12-iso-iPF(2a)-VI, respectively.
4.4 | Statistical analyses
Baseline characteristics were compared using Wilcoxon–Mann–Whit-
ney test and Fisher’s exact test. Spearman correlations examined
relationships between baseline characteristics and F2-isoprostanes at
baseline. The same statistical methodologies as used in the parent
RCT analysis were applied (Rochon et al., 2011). Intention-to-treat
(ITT) analyses were performed by including all available observations
in the analysis (see CONSORT diagram, Supplemental Material). Simi-
lar to the impact in drug trials, in this context, use of ITT analysis is
intended to generate group differences that are similar to that
expected in a similar population, incorporating level of compliance.
All statistical tests were conducted at a two-tailed type I error level.
Results were generated using SAS version 9.2 and higher.
4.4.1 | Primary analysis
Repeated-measures analysis of covariance was applied with change
from baseline as the dependent variable; treatment, time, and the
treatment-by-time interaction were independent variables; site, sex,
BMI stratum, and baseline values of the biomarkers were covariates.
The primary hypothesis was tested by defining contrasts among the
regression parameters; the predicted mean  standard error (se) are
the adjusted values from this model. Type I error was controlled
using a gatekeeping strategy (Dmitrienko & Tamhane, 2007). Com-
parisons were only performed at a = 0.05 if significance was
a = 0.05 at the higher level in the hierarchy; otherwise, Bonferroni’s
correction was applied by multiplying the nominal p-value by number
of tests (truncated at 1.0) (Wright, 1992).
4.4.2 | Exploratory analyses
Using methods similar to the primary hypothesis testing, the
exploratory analyses examined associations between three F2-iso-
prostane species iPF(2a)-III, iPF(2a)-VI, and 8,12-iso-iPF(2a)-VI and
caloric restriction. We observed a strong correlation between the
four individual F2-isoprostane species, indicating a redundancy in
the information contained in the individual measures. To take sta-
tistical advantage of this intercorrelation, we performed a factor
analysis to define a combined variable, or factor, containing this
common information at baseline. The advantage of a single sum-
mary variable comprised of the information held in common by a
set of variables is that it is more reliable than any one single indi-
cator, and the analysis of this summary variable avoids type I error
issues inherent in the testing of multiple outcomes. This iso-
prostane factor was analyzed in a manner similar to the analysis of
the primary hypothesis. In addition, we explored the correlations
among F2-isoprostanes, metabolic factors, and hormones known to
be affected by CR: leptin, adiponectin, C-reactive protein, fasting
insulin, triiodothyronine, and insulin sensitivity (Fontana, Klein, Hol-
loszy & Premachandra, 2006; Fontana, Meyer, Klein & Holloszy,
2004; Fontana et al., 2010; Lecoultre, Ravussin & Redman, 2011;
Longo & Fontana, 2010).
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